Crinetics Pharmaceuticals Free Cash Flow (FCF) History (CRNX)
Crinetics Pharmaceuticals reported −$383.7M in free cash flow for fiscal 2025, a decrease of $149.6M from the previous fiscal year, with a free cash flow margin of −4985.50%.
View full Crinetics Pharmaceuticals company overviewCrinetics Pharmaceuticals free cash flow by year
| Fiscal year | Period ended | Free cash flow | Change | Growth | FCF margin |
|---|---|---|---|---|---|
| 2025 | 2025-12-31 | −$383.7M | −$149.6M | — | −4985.50% |
| 2024 | 2024-12-31 | −$234.0M | −$60.8M | — | −22525.31% |
| 2023 | 2023-12-31 | −$173.3M | −$56.4M | — | −4318.12% |
| 2022 | 2022-12-31 | −$116.9M | −$27.8M | — | — |
| 2021 | 2021-12-31 | −$89.0M | −$26.8M | — | — |
| 2020 | 2020-12-31 | −$62.2M | −$15.3M | — | −87623.94% |
| 2019 | 2019-12-31 | −$46.9M | −$26.4M | — | −3929.00% |
| 2018 | 2018-12-31 | −$20.5M | −$10.7M | — | −845.06% |
| 2017 | 2017-12-31 | −$9.8M | −$4.1M | — | −478.39% |
| 2016 | 2016-12-31 | −$5.7M | — | — | −960.61% |
Crinetics Pharmaceuticals quarterly free cash flow
| Fiscal quarter | Period ended | Free cash flow | Change | YoY growth | FCF margin |
|---|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | −$94.7M | −$5.7M | — | −377.08% |
| Q1 2026 | 2026-03-31 | −$125.5M | −$35.8M | — | −1169.40% |
| Q4 2025 | 2025-12-31 | −$93.4M | −$25.5M | — | −1515.32% |
| Q3 2025 | 2025-09-30 | −$111.6M | −$48.2M | — | −78028.67% |
| Q2 2025 | 2025-06-30 | −$89.1M | −$40.5M | — | −8637.54% |
| Q1 2025 | 2025-03-31 | −$89.7M | −$35.5M | — | −24845.15% |
| Q4 2024 | 2024-12-31 | −$67.9M | −$26.2M | — | — |
| Q3 2024 | 2024-09-30 | −$63.4M | −$18.5M | — | — |
| Q2 2024 | 2024-06-30 | −$48.6M | −$2.6M | — | −12180.20% |
| Q1 2024 | 2024-03-31 | −$54.2M | −$13.5M | — | −8466.88% |
| Q4 2023 | 2023-12-31 | −$41.7M | −$6.3M | — | — |
| Q3 2023 | 2023-09-30 | −$44.8M | −$5.7M | — | −12959.25% |
| Q2 2023 | 2023-06-30 | −$46.0M | −$17.4M | — | −4653.04% |
| Q1 2023 | 2023-03-31 | −$40.7M | −$27.1M | — | −1520.49% |
| Q4 2022 | 2022-12-31 | −$35.5M | −$12.6M | — | — |
| Q3 2022 | 2022-09-30 | −$39.2M | −$13.3M | — | −8550.44% |
| Q2 2022 | 2022-06-30 | −$28.6M | −$8.5M | — | −6512.30% |
| Q1 2022 | 2022-03-31 | −$13.6M | $6.6M | — | −435.32% |
| Q4 2021 | 2021-12-31 | −$22.9M | −$7.0M | — | — |
| Q3 2021 | 2021-09-30 | −$25.8M | −$7.7M | — | — |
| Q2 2021 | 2021-06-30 | −$20.1M | −$4.2M | — | — |
| Q1 2021 | 2021-03-31 | −$20.2M | −$7.9M | — | — |
| Q4 2020 | 2020-12-31 | −$16.0M | −$2.5M | — | — |
| Q3 2020 | 2020-09-30 | −$18.1M | −$4.5M | — | — |
| Q2 2020 | 2020-06-30 | −$15.9M | −$3.2M | — | — |
| Q1 2020 | 2020-03-31 | −$12.3M | −$5.1M | — | −17309.86% |
| Q4 2019 | 2019-12-31 | −$13.5M | −$7.2M | — | −4197.82% |
| Q3 2019 | 2019-09-30 | −$13.6M | −$7.7M | — | −2694.46% |
| Q2 2019 | 2019-06-30 | −$12.6M | −$7.8M | — | — |
| Q1 2019 | 2019-03-31 | −$7.2M | −$3.7M | — | −1952.86% |
| Q4 2018 | 2018-12-31 | −$6.3M | −$3.8M | — | −805.51% |
| Q3 2018 | 2018-09-30 | −$5.9M | — | — | −1084.67% |
| Q2 2018 | 2018-06-30 | −$4.8M | — | — | −733.49% |
| Q1 2018 | 2018-03-31 | −$3.5M | — | — | −783.71% |
| Q3 2017 | 2017-09-30 | −$2.5M | — | — | −384.53% |
Crinetics Pharmaceuticals free cash flow growth trends
Over the last five reported fiscal years, free cash flow declined from −$62.2M to −$383.7M, a net decrease of $321.5M. Crinetics Pharmaceuticals's latest reported quarter, Q2 2026, generated −$94.7M in free cash flow, a decrease of $5.7M year over year.
What free cash flow means
Free cash flow is the cash a company generates from operations after capital expenditures. Positive FCF can fund dividends, buybacks, debt repayment, or reinvestment; negative FCF means capital spending exceeded operating cash flow for that period.
How free cash flow is calculated
TickerStat calculates free cash flow as SEC-reported operating cash flow minus capital expenditures. FCF margin equals free cash flow divided by revenue. Fiscal periods can differ from calendar years, so the tables include exact period-end dates.
Review Crinetics Pharmaceuticals filings at SEC.gov ↗